TED A9
Alternative Names: A9-DPC; Allogenic embryonic stem cell-derived A9 dopamine progenitor cell therapy - S.Biomedics; hESC-derived dopaminergic progenitors - S.Biomedics; TED-A9Latest Information Update: 02 Dec 2024
Price :
$50 *
At a glance
- Originator S.Biomedics
- Class Stem cell therapies
- Mechanism of Action Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Parkinson's disease
Most Recent Events
- 26 Nov 2024 Updated efficacy and adverse events data from a phase I/II trial in Parkinson's disease released by S.Biomedics
- 09 Jul 2024 Adverse events and efficacy data from a phase I/II trial in Parkinson's disease released by S.Biomedics
- 29 Feb 2024 Interim adverse events data from a phase I/II trial in Parkinson's disease released by S.Biomedics